Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections / 医学前沿
Frontiers of Medicine
;
(4): 644-648, 2021.
Article
Dans Anglais
| WPRIM
| ID: wpr-888748
ABSTRACT
The coronavirus disease 2019 (COVID-19) has caused global public health and economic crises. Thus, new therapeutic strategies and effective vaccines are urgently needed to cope with this severe pandemic. The development of a broadly neutralizing antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is one of the attractive treatment strategies for COVID-19. Currently, the receptor-binding domain (RBD) of the spike (S) protein is the main target of neutralizing antibodies when SARS-CoV-2 enters human cells through an interaction between the S protein and the angiotensin-converting enzyme 2 expressed on various human cells. A single monoclonal antibody (mAb) treatment is prone to selective pressure due to increased possibility of targeted epitope mutation, leading to viral escape. In addition, the antibody-dependent enhancement effect is a potential risk of enhancing the viral infection. These risks can be reduced using multiple mAbs that target nonoverlapping epitopes. Thus, a cocktail therapy combining two or more antibodies that recognize different regions of the viral surface may be the most effective therapeutic strategy.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Anticorps neutralisants
/
Glycoprotéine de spicule des coronavirus
/
SARS-CoV-2
/
COVID-19
/
Anticorps monoclonaux
/
Anticorps antiviraux
Limites du sujet:
Humains
langue:
Anglais
Texte intégral:
Frontiers of Medicine
Année:
2021
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS